MedsFacts Meta-Analysis covering adverse side effect reports of CALCITRAN B12 patients who developed OSTEOPENIA.

Introduction: MedsFacts provides MD-approved analysis to help both patients and physicians accurately research and assess the risk-reward trade off for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration, social media, and MedsFacts user submissions. Between January 2004 and October 2012, 1 individuals taking CALCITRAN B12 reported OSTEOPENIA to the FDA. A total of 2 CALCITRAN B12 drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

Topics covered: This page is designed to help you determine the relationship, if any, between CALCITRAN B12 and OSTEOPENIA. In doing so, we compare CALCITRAN B12 with other drugs that cause OSTEOPENIA, to help you evaluate whether or not CALCITRAN B12 causes OSTEOPENIA. Likewise, this page shows the most highly-reported side effects of CALCITRAN B12, so you can see if OSTEOPENIA ranks among CALCITRAN B12's most well-known side effects.

The Dashboard explained: The Dashboard first shows general Summary Statistics for CALCITRAN B12 and OSTEOPENIA, such as the raw number and percentage of patients in FDA reports who used CALCITRAN B12 and developed OSTEOPENIA. Next, the Dashboard lists the most common reasons (indications) why CALCITRAN B12 was prescribed for patients. We then display a pie-chart which shows, in aggregate, what we believe represents general physician opinion of the safety of CALCITRAN B12. This pie-chart summarizes, for all FDA reports covering CALCITRAN B12, whether or not the treating physician felt CALCITRAN B12 (versus other drugs the patient was taking) was responsible for the adverse side-effects. After the pie-chart, we itemize the most common side effects in FDA studies covering CALCITRAN B12. You may click on any of these side effects to learn more about them, in general, or specifically for CALCITRAN B12. Finally, we identify the drugs most widely associated with CALCITRAN B12 in FDA literature. You may also click on any of these drugs to view it's dashboard.

Dashboard view of our research literature concerning CALCITRAN B12 :

Summary Statistics
Reports of CALCITRAN B12 causing OSTEOPENIA: 1
Reports of any side effect of CALCITRAN B12 : 2
Percentage of CALCITRAN B12 patients where OSTEOPENIA is a reported side effect: 50%

FDA reports of any drug causing OSTEOPENIA : 6844
Average percentage for all medicated patients where OSTEOPENIA is reported as a complication: 0.042894151911356%
Most frequent diagnoses/indications for prescribing CALCITRAN B12:
Physician opinion on CALCITRAN B12 as adverse event culprit:

(* global)
Twitter feed for CALCITRAN B12 - Pending/Beta

Basic reports are available, free of charge, in PDF format and are suitable for scientific publication. Further data and analytics are available upon request. We are in the process of adding new features to our site, including Q&A interface for patients to speak with experts on medication. Check back with us again in the near future to see.

Copyright 2013 MedsFacts
Privacy Policy
Terms of use